pathogenesis of accelerated atherosclerosis and are an independent risk marker leading to end-stage renal disease and mortality. Circulating ADMA is metabolized by the action of dimethylarginine dimethylamino hydrolase (DDAH) and DDAH2 isoform is the most prevalent in tissues expressing endothelial NOS. DDAH and NOS are co-expressed in the same kidney regional sites supporting the hypothesis that a strict and specific regulation of intracellular ADMA levels is crucial for NO generation in the kidney. Starting from these findings, the study aims to investigate the role of DDAH2 gene promoter polymorphism at position -1151 A/C in determining the levels of ADMA in type 2 diabetic patients (T2DM) with chronic renal impairment. Methods. Three groups of carefully selected subjects of both sexes were enrolled and compared. The first group (control subjects) comprised 286 non-diabetic subjects (mean age 55.8 ± 11.4 years), the second group (T2DM uncomplicated subjects) was made up of 322 T2DM subjects without complications (mean age 64.9 ± 9.6 years) whereas the third group (T2DM CRF subjects) included 110 T2DM patients with chronic renal impairment. The rs805304 DDAH2-1151 A/C promoter polymorphism was determined by a polymerase chain reaction-restriction fragment length polymorphism approach.
Results. T2DM CRF subjects showed significant increased plasma levels of ADMA with respect to those of T2DM uncomplicated subjects and control subjects (0.51 versus 0.39 versus 0.37 μmol/L, P = 0.002, respectively). Analysis of variance showed an interaction between DDAH2-1151 C carrier and groups on ADMA plasma levels (F = 4.36; P < 0.05). ADMA plasma levels were also dependent on groups (F = 4.96; P < 0.01). Conclusions. Our work demonstrates that rs805304 DDAH2-1151 polymorphism plays a central role in determining ADMA in diabetic renal impairment, where patients with DDAH2-1151 C carriers showed the highest ADMA levels. This unfavourable genetic profile is highlighted by pathological kidney conditions such as diabetic CRF. These findings could open new insights on the pathways involving ADMA/DDAH/NOS in the development and progression of chronic renal impairment and therefore of the other micromacrovascular diabetic complications.
I N T RO D U C T I O N
There is a large body of evidence that endothelial dysfunction in renal impairment is characterized by decreased vasodilation, proinflammatory state and prothrombic properties of the endothelium [1] . Endothelial dysfunction has been clearly demonstrated to worsen prognosis for cardiovascular events. The endothelial derangement leading to impaired vasodilation is mediated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS) [2] . It inhibits nitric oxide (NO) production at concentrations found in pathophysiological conditions, and causes local vasoconstriction when infused intra-arterially in humans [3] . ADMA is generated by protein methyltransferase (PRMT) and is metabolized by dimethylarginine dimethylaminohydrolase (DDAH). ADMA levels are reported to increase in patients with a chronic kidney disease, thereby playing a role in the pathogenesis of accelerated atherosclerosis in these subjects. However, the precise mechanism underlying ADMA accumulation is not fully understood in these patients [4] . This molecule has gained the role of new marker of cardiovascular disease (CVD) in association with endothelial dysfunction, insulin resistance and atherosclerosis [5] . NO is synthesized by the action of a specific enzyme, NOS, that catalyses the oxidation of the terminal guanidine nitrogen of Larginine. In patients with a chronic kidney disease, ADMA is a strong and independent risk marker for a worsening in renal function, progression to end-stage renal disease and mortality [6, 7] . ADMA decreases renal plasma flow and increases renovascular resistance in a dose-related manner [8] . Moreover, administration of ADMA causes significant sodium retention and blood pressure increase [3] . Quantification of ADMA improves risk stratification [7, 9] . It is well known that more than 80% of the circulating ADMA is metabolized by the action of DDAH that specifically degrades ADMA to L-citrulline and dimethylamine [10] . Increased plasma ADMA levels are found in pathological conditions associated with CVD such as hypercholesterolaemia, hyperhomocysteinaemia, hypertension, insulin resistance and diabetes mellitus. High values of ADMA are associated with all causes of death but not with CVD occurrence in subjects without diabetes, suggesting that the role of ADMA in diabetes is probably more complex and probably linked to increased oxidative stress [11] . They seem to be related to high susceptibility of DDAH to oxidative stress [12] . DDAH exists in two isoforms, of which, DDAH 2 is the prevalent form in tissues that express endothelial NOS. Moreover, Tojo et al. [13] have reported that these enzymes are co-expressed in the same kidney regional sites supporting the hypothesis that a strict and specific regulation of intracellular ADMA levels is crucial for NO generation in the kidney. It was recently reported that reduced DDAH expression could contribute to ADMA accumulation and a subsequent increase in blood pressure in an experimental model of a chronic kidney disease [14] . In addition, another study has highlighted the role of the genetic variation of DDAH2 gene and its association with an ADMA levels in type 2 diabetic patients with retinopathy [15] . Starting from these findings, this study was aimed to investigate the role of rs805304 DDAH2-1151 A/C promoter polymorphism in determining the levels of ADMA in diabetic subjects with chronic renal impairment.
M AT E R I A L S A N D M E T H O D S

Subject populations
Two hundred and eighty-six non-diabetic subjects (control subjects, CS), 320 type 2 diabetic subjects without complications (T2DM uncomplicated subjects) and 110 type 2 diabetic subjects with chronic renal impairment (T2DM CRF subjects) were enrolled after informed consent was obtained from each subject. The study protocol was approved
by the Institutional Review Board of the INRCA Hospital. T2DM was diagnosed according to the American Diabetes Association Criteria [16] . Inclusion criteria were BMI <40 kg/ m 2 , age 35-85 years, ability and willingness to give written informed consent and to comply with the requirements of the study. Information collected included data on vital signs, anthropometric factors, medical history and behaviours as well as physical activity. DNA was collected from participants providing consent to use genetic material (100% of the sample). The presence/absence of diabetic complications was evidenced as follows: diabetic retinopathy by fundoscopy through dilated pupils and/or fluorescence angiography; renal impairment, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 evaluated using the CKD-EPI equation [17] ; neuropathy established by electromyography; ischaemic heart disease defined by clinical history and/or ischaemic electrocardiographic alterations; peripheral vascular disease including atherosclerosis obliterans and cerebrovascular disease on the basis of history, physical examinations and Doppler velocimetry. Hypertension was defined as a systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg, measured while the subjects were sitting, which was confirmed in at least three different occasions. BMI was calculated as weight (kg)/height (m) 2 . All the selected subjects were Italian and consumed a Mediterranean diet. Overnight fasting venous blood samples of all subjects were collected from 8:00 to 9:00 a.m. in plain, EDTA, heparin and citrate-added tubes. The samples were either analysed immediately or stored at −80°C for no more than 30 days.
Assays of blood parameters
Blood concentrations of fasting glucose, HbA1c, fasting insulin, total cholesterol, high-density lipoprotein, triglycerides and creatinine were measured by standard laboratory procedures.
ADMA, SDMA and L-arginine determination It was accomplished by high-performance liquid chromatography, using a method recently developed by our group [18] . Briefly, 200 μL of plasma was supplemented with 20 μL of N-PLA (Nω-Propyl-L-arginine) 231 μM working solution (internal standard), diluted with 50 mM borate buffer pH 8.5. The sample was loaded in a pre-conditioned solid phase extraction column, washed and finally ADMA, SDMA and Larginine were extracted from plasma samples using a freshly prepared aqueous solution containing 10% v/v NH 4 OH and 50% v/v methanol. The eluent was then evaporated to dryness at 40°C under nitrogen and the dried extract dissolved in 240 μL of 50 mM borate buffer pH 8.5. After addition of 30 μL of 5 mM potassium cyanide in the same borate buffer and of 30 μL of NDA 5 mM (naphthalene-2,3-dicarboxaldehyde) as derivative agent was added. The derivatized samples were injected into the column and eluted using a mobile phase of 25 mM sodium acetate buffer containing 38% v/v of methanol ( pH = 6.8). The flow rate was set at 1.0 mL/min and the wavelengths of fluorescence detector were set at 420 and 483 nm for excitation and emission, respectively. Peak areas were used for quantification. 
DDAH2-1151 (C/A) polymorphism
Statistical analysis
Data were analysed with SPSS/Win program (version 18.0; SPSS Inc., Chicago, IL, USA). The skewed distributions were log transformed before statistical analyses to achieve a normal distribution. Their results are shown as median and interquartile range (IQR). Differences among control subjects, T2DM uncomplicated subjects and T2DM CRF subjects were compared using one-way analysis of variance (ANOVA) for continuous variables and χ 2 test for categorical variables. Scheffè multiple comparisons were performed when appropriate. The distributions of DDAH2-1151 A/C polymorphism and the Hardy-Weinberg equilibrium were analysed by the χ 2 test. The differences among DDAH2-1151 genotypes were compared using one-way ANOVA or Student's t-test when dominant [(AA + AC) versus CC] or recessive [AA versus (AC + CC)] genetic models were considered. Two-factor ANOVA was performed to investigate the differences for Larginine, ADMA and SDMA levels among groups and DDAH2-1151 C carrier. Custom hypothesis tests were applied to verify the differences for L-Arginine, ADMA and SDMA levels in the interaction between the groups and DDAH2-1151 C carrier. Then, the ordinal logistic regression analysis was used to analyse if the ADMA levels on T2DM CRF subjects differed depending on the DDAH-1151 genotype. The results are expressed as adjusted odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). For this analysis, ADMA levels were categorized according to the total median value. Probability values of <0.05 were considered statistically significant.
R E S U LT S
The anthropometric, clinical and laboratory parameters for the studied subjects are reported in Table 1 . Age, fasting glucose, HbA1c, fasting insulin, HOMA index and triglycerides were significantly higher in T2DM CRF patients with respect to T2DM uncomplicated subjects. In particular, T2DM CRF patients showed higher values compared with the CS. As expected, T2DM CRF patients showed significantly increased creatinine serum levels compared with CS and T2DM uncomplicated subjects as well as expected lower eGFR. Plasma levels of ADMA and SDMA showed statistically significant differences among groups. In particular, plasma ADMA levels in T2DM CRF subjects showed the highest value with respect to the other groups, whereas SDMA levels were statistically different among all groups. No differences were found for L-arginine plasma levels among groups. All the enrolled subjects were also analysed for DDAH2-1151 A/C polymorphism. Genotype distribution and allele frequencies of DDAH2-1151 A/C polymorphism are reported in Table 2 . The genotype frequencies distribution of the DDAH2-1151 A/C polymorphism was in the Hardy-Weinberg equilibrium in all studied groups (P > 0.05). As reported in Table 2, Table 3 . No differences were found for the reported variable using a dominant and recessive model as well as when using DDAH genotypes (data not shown). In particular, regarding ADMA plasma levels, the Table 3 . Plasma L-arginine, SDMA, ADMA, creatinine and eGFR according to DDAH genotypes in the whole population studied model failed to reach statistical significance (P = 0.061). Then, we applied an ANOVA model in order to verify the relationship of the studied variables (L-arginine, SDMA and ADMA) with the presence of CRF and DDAH2-1151 C+/C− carrier and A+/A− carrier. The results are reported in Table 4 . This analysis showed an interaction between C carriers and groups on ADMA plasma levels (F = 4.36; P < 0.05). The significance of the analysis still remained considering only ADMA levels and groups (F = 4.96; P < 0.01). SDMA plasma levels, as expected, were only dependent on groups (F = 33.29; P < 0.01), whereas no relationship was found for L-arginine. When considering A carrier in the analysis, we found a statistically significant interaction between ADMA plasma levels and groups (F = 3.37; P < 0.05) and SDMA plasma levels and groups (F = 18.21; P < 0.01). In Figure 1 , the differences in ADMA between DDAH2-1151 C+ carrier subjects and C− group in the three studied groups have been reported. It is clearly visible that the mean values of ADMA are significantly higher in C+ T2DM CRF subjects with respect to those in C − T2DM CRF subjects and higher than all the other evaluated groups regardless of the presence of the C allele. Furthermore, the ordinal logistic regression analysis confirmed that the relationship between ADMA levels and T2DM CRF subjects varied as a function of the DDAH-1151 C carrier. The effect of ADMA levels on T2DM CRF subjects was moderated by the C+ carrier. Subjects with higher ADMA levels and C+ carrier had a higher probability to be T2DM CRF patients (OR = 2.11, P = 0.009, 95% CI = 1.21-3.69).
D I S C U S S I O N
Since Vallance et al. [19] discovered ADMA in 1992 as the mainly NOS inhibitor, numerous papers have been written to explain the role of ADMA in chronic kidney disease. Several papers have reported the association between the pathological conditions that underlie chronic kidney disease such as the accumulation of uraemic toxins, infections and inflammation Table 4 . ANOVA for L-arginine, ADMA and SDMA between groups and DDAH2-1151 C carrier and A carrier in determining plasma ADMA levels [20] . However, the discovery of DDAH as a key enzyme in the catabolism of ADMA [7, 8, 21] has opened a new route to search for the pathways leading to the regulation of ADMA levels. In particular, Jones et al. [22] investigating the role of the polymorphism of DDAH have highlighted that regulatory elements are present within the DDAH2 promoter gene and that variants determine the enzyme expression. In light of these scientific papers, our study aimed to investigate the role of DDAH2-1151 A/C polymorphism in determining ADMA plasma levels in type 2 diabetic patients with chronic renal impairment. The main finding of our work was to demonstrate that an interaction between DDAH2-1151 C carriers and the tested groups on ADMA plasma levels exists, as reported in Table 4 . This, to the best of our knowledge, is the first time that a clear demonstration of a relationship between DDAH promoter polymorphism and chronic renal impairment is shown. The effect of this interaction is that T2DM CRF subjects bearing DDAH2-1151 C allele show the highest ADMA levels with respect to subjects not carrying C allele, as shown in Figure 1 . Interestingly, DDAH2-1151 genotype frequencies were not different between the three studied groups, suggesting that if there is an impact on renal failure, this is most likely due to the pathological condition associated with kidney disease and not with a genetic predisposition. This fundamental observation has a profound implication in the pathophysiological outcome on the prognosis and progression of CRF complication and deserves to give explanation. One conceivable elucidation could be that C+ carrier subjects have an unfavourable genetic profile which produces an enzyme more sensitive to damage in pathological conditions such as chronic renal impairment. Our opinion has been supported by several papers showing that accumulation of ADMA in patients with kidney dysfunction might be related to renal parenchymal damage, rather than reduced glomerular filtration of ADMA, and resulting in an overall reduction in expression and activity of DDAH, which are present in abundance in the endothelial cells of the glomerulus, vessels and tubular cells [8, 20] . Furthermore, our study confirms their observation that DDAH2-1151 A/C polymorphism has no association with eGFR. Nevertheless, increased ADMA levels have also a regulatory mechanism in the pathological overproduction of NO associated with infection/inflammation [23] that might be present in renal impairment. In addition, it has been proposed that glomerular permeability to protein is regulated by NO bioavailability and consequently superoxide [24] . Inhibition of NOS, i.e. by increased ADMA levels, could lead to NOS uncoupling and increase superoxide production that can be reduced by superoxide scavengers and/or NO donors [25] . The increase in oxidative stress is reported in hypertensive patients with microalbuminuria [26] and in T2DM subjects [27] . Moreover, it is interesting to note that we found an association with DDAH2 promoter polymorphism and another microvascular complication of diabetes that involved, in the early phases, endothelial dysfunction that came from the decrease in ADMA catabolism caused by oxidative stress and inflammation [15] . All the aforementioned conditions have been proposed to impair DDAH activity in vivo and/or in vitro, and might be present in CRF subjects and contribute to various degrees in increasing ADMA levels, worsening the damaging effects on the enzyme integrity. Regarding SDMA plasma levels, we observed a significantly lower value in the diabetic uncomplicated group with respect to the control group, whereas the diabetic CRF group obviously shows, as expected, the highest levels. We have also noticed that no significant difference was found between controls and diabetic uncomplicated subjects in ADMA values. We suppose that this result could depend on the strict adopted selection criteria of the population studied, especially in defining uncomplicated diabetic subjects that leads to the enrollment of patients in fairly good metabolic control [28] . Our work is limited by the cross-sectional study design that does not permit to determine the causality. At the same time, the strength of the present study design is that we included only control subjects and T2DM uncomplicated subjects which allowed us also to investigate the role of DDAH2-1151 A/C promoter polymorphism in determining the levels of ADMA in diabetic subjects with renal impairment free from other confounding outcomes. In conclusion, our findings open a new insight into the pathways involving ADMA/DDAH/NOS in the development and progression of chronic renal impairment in type 2 diabetic patients. Our suggestion is that the impairment filtration in CRF patients highlights the low ability of the C+ carrier to metabolize ADMA with the respect to C−. Since DDAH2 is most abundantly expressed in tissues where endothelial NOS is also present (such as the heart, vascular wall and lung) we hypothesize that, in consequence, this ADMA impairment found in CRF C+ carriers could lead to an increased risk for CVD in these patients.
F I G U R E 1 : Differences of median ADMA plasma levels between DDAH2-1151 C+ carrier subjects and C− carrier subjects in the three studied groups.
